Company
Headquarters: Taipei, Taiwan
Employees: 89
TW$4.23 Billion
TWD as of July 1, 2024
US$129.8 Million
Company | Market Cap (USD) |
---|---|
Novo Nordisk | $622.07 B |
Vertex Pharmaceuticals Incorporated | $121.36 B |
Regeneron Pharmaceuticals, Inc. | $115.11 B |
CSL Limited | $95.75 B |
Marinomed Biotech AG | $75.67 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Intech Biopharm Corporation focuses on developing and manufacturing generic drugs to treat respiratory diseases. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform to treat asthma and chronic pulmonary obstructive disease; and dry powder inhaler. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation is headquartered in Taipei, Taiwan.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Intech Biopharm Corp has the following listings and related stock indices.
Stock: TWSE: 6461 wb_incandescent